Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Renal Transplant Unit, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.
HLA. 2024 Jan;103(1):e15297. doi: 10.1111/tan.15297.
In kidney transplantation, donor HLA antibodies are a risk factor for graft loss. Accessibility of donor eplets for HLA antibodies is predicted by the ElliPro score. The clinical usefulness of those scores in relation to transplant outcome is unknown. In a large Dutch kidney transplant cohort, Ellipro scores of pretransplant donor antibodies that can be assigned to known eplets (donor epitope specific HLA antibodies [DESAs]) were compared between early graft failure and long surviving deceased donor transplants. We did not observe a significant Ellipro score difference between the two cohorts, nor significant differences in graft survival between transplants with DESAs having high versus low total Ellipro scores. We conclude that Ellipro scores cannot be used to identify DESAs associated with early versus late kidney graft loss in deceased donor transplants.
在肾移植中，供体 HLA 抗体是移植物丢失的一个风险因素。ElliPro 评分可预测供体肽段对 HLA 抗体的可及性。这些评分与移植结果的临床相关性尚不清楚。在一个大型的荷兰肾移植队列中，我们比较了可分配给已知肽段的（供体表位特异性 HLA 抗体[DESAs]）移植前供体抗体的 Ellipro 评分，这些抗体在早期移植物失功和长期存活的已故供体移植之间。我们没有观察到两个队列之间 Ellipro 评分有显著差异，也没有观察到具有高总 Ellipro 评分与低总 Ellipro 评分的 DESAs 移植之间在移植物存活率方面有显著差异。我们的结论是，Ellipro 评分不能用于识别与已故供体移植中早期与晚期肾移植物丢失相关的 DESAs。
